Overview

* Femasys ( FEMY ) Q3 sales increased 31.4% yr/yr, driven by FemBloc sales

* Company reduced Q3 net loss compared to prior year

* Femasys ( FEMY ) secured $12 mln financing

Outlook

* Company expects cash to fund operations into September 2026

* Femasys ( FEMY ) advancing toward U.S. approval of FemBloc

* Company expanding FemBloc commercialization in Europe and Asia-Pacific

Result Drivers

* FEMBLOC SALES - Sales increase driven by FemBloc, a non-surgical permanent birth control product

* REGULATORY APPROVALS - UK and New Zealand approvals expand FemBloc market reach

* COST REDUCTION - Decreased R&D expenses due to commercialization and reduced costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.10

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Femasys Inc ( FEMY ) is $6.00, about 86.2% above its November 13 closing price of $0.83

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)